GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Other Current Assets

Oncodesign Precision Medicine (XPAR:ALOPM) Other Current Assets

: €0.16 Mil (As of Jun. 2022)
View and export this data going back to 2022. Start your Free Trial

Oncodesign Precision Medicine's other current assets for the quarter that ended in Jun. 2022 was €0.16 Mil.

Oncodesign Precision Medicine's quarterly other current assets declined from Dec. 2020 (€0.19 Mil) to Dec. 2021 (€0.05 Mil) but then increased from Dec. 2021 (€0.05 Mil) to Jun. 2022 (€0.16Mil).

Oncodesign Precision Medicine's annual other current assets increased from . 20 (€0.00 Mil) to Dec. 2020 (€0.19 Mil) declined from Dec. 2020 (€0.19 Mil) to Dec. 2021 (€0.05 Mil).


Oncodesign Precision Medicine Other Current Assets Historical Data

The historical data trend for Oncodesign Precision Medicine's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21
Other Current Assets
0.19 0.05

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22
Other Current Assets 0.19 0.05 0.16

Oncodesign Precision Medicine Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


Oncodesign Precision Medicine Other Current Assets Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines